Effect of Clostridium Butyricum Against Microglia-Mediated Neuroinflammation in Alzheimer's Disease Via Regulating gut Microbiota and Metabolites Butyrate.
Recent evidences demonstrated that abnormal gut microbiota (GM) might be involved in the pathogenesis of Alzheimer's disease (AD). However, the role of probiotics in preventing AD by regulating GM-gut-brain axis remain unclear. Here, we investigated the anti-neuroinflammatory effect and its mechanism of probiotic Clostridium butyricum (CB) against AD by regulating GM-gut-brain axis. APPswe/PS1dE9 (APP/PS1) transgenic were treated intragastrically with CB for 4 weeks then cognitively tested. Amyloid-β (Aβ) burden, microglial activation, proinflammatory cytokines production, GM and metabolites butyrate were analyzed. Moreover, Aβ-induced BV2 microglia were pretreated with butyrate, and the levels of cluster of differentiation 11b (CD11b), cyclooxygenase-2 (COX-2) and NF-κB p65 phosphorylation were determined. Our results exhibited that CB treatment prevented cognitive impairment, Aβ deposits, microglia activation and production of tumor necrosis factor (TNF)-α and interleukin (IL)-1β in the brain of APP/PS1 mice. Meanwhile, abnormal GM and butyrate were reversed after CB treatment. Notably, butyrate treatment reduced the levels of CD11b and COX-2, and suppressed phosphorylation of NF-κB p65 in the Aβ-induced BV2 microglia. These findings indicated that CB treatment could attenuate microglia-mediated neuroinflammation via regulating the GM-gut-brain axis, which was mediated by the metabolite butyrate. This article is protected by copyright. All rights reserved.